Lowest Price Guaranteed From USD 5,899
Published
July 2022
Pages
580
View Count
14685
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
In the past two decades, antibody therapeutics have become a key component of the treatment regimens against a range of diseases, specifically cancer. Representing one of the rapidly growing segments of the pharmaceutical industry, a number of technological advancements have been reported in this sector. In this context, a number of researchers are evaluating the potential of antibody drug conjugates (ADCs) for the treatment of a myriad of disease indications. In addition to enabling better efficacy as compared to antibody therapeutics, ADCs exhibit higher stability, reduced toxicity, improved tumor selectivity, increased drug tolerance and less systemic exposure. It is worth highlighting that, in the last few years, more than 10 ADCs have received the FDA approval. Further, a number of ADCs are being evaluated across 700+ clinical trials for the treatment of a wide array of disorders. To support the ongoing pace of research in this domain, a total of USD 14.8 billion (since 2014) has been the investment in ADCs domain by several private / strategic investors and government organizations, indicating the therapeutic potential and growing appeal of this unique class of targeted medicines. However, the production of this therapeutics is associated with several challenges, including generation of antibody aggregates, drug / linker side reactions, containment of highly toxic drug compounds, and lot-to-lot variation in drug-antibody ratio (DAR). Moreover, the manufacturing process often requires the use of cutting-edge linker technologies, which are expensive to acquire.
In order to mitigate the abovementioned challenges associated with ADC manufacturing, around 70-80% players engaged in this domain prefer to outsource their operations to contract manufacturing organizations (CMOs) having the required expertise and experience, in order to leverage their capabilities and yield cost savings opportunities. Currently, the ADC contract manufacturing market landscape is highly fragmented, featuring a mix of start-ups, mid-sized firms and well-established players. Moreover, stakeholders claim to offer a range of services, across different scales of operations; over 35% of such companies have established their facilities across different geographies. Owing to the fact that a number of ADC developers are outsourcing various aspects of their business processes, CMOs engaged in this domain have undertaken several expansion initiatives to become one-stop-shops to cater to the diverse needs of ADC developers. Moreover, given the projected increase in demand for ADCs, the associated contract manufacturing market is anticipated to witness substantial growth in the coming years.
The “ADC Contract Manufacturing Market (5th Edition) by Phase of Development (Phase I, Phase II and Phase III), Scale of Operation (Clinical and Commercial), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), Antibody Isotype (IgG1and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World), 2022-2035” report features an extensive study of the current market landscape and the likely future potential associated with the ADC contract manufacturing market, over the next decade. The study includes an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. Amongst other elements, the report features:
One of the key objectives of the report was to estimate the current opportunity and future size of the ADC contract manufacturing market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, over the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] Phase of Development (Phase I, Phase II and Phase III), [B] Scale of Operation (Clinical and Commercial) [C] Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), [D] Target Indications (Solid Tumors, Hematological Malignancies and Others), [E] Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), [F] Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), [G] Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), [H] Type of Antibody Isotype (IgG1and Others) and [I] Geography (North America, Europe, Asia-Pacific and Rest of World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s revolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the ADC contract manufacturing market and its likely evolution in the mid to long term.
Chapter 3 provides a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, along with information on the key manufacturing steps involved. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.
Chapter 4 provides a detailed overview of the overall market landscape of players engaged in the contract manufacturing of ADCs, based on several relevant parameters, such as company size, year of establishment, location of headquarters, type of service(s) offered (antibody manufacturing, HPAPI and payload synthesis, linker manufacturing, conjugation and fill-finish), other ADC service(s) offered (proof-of-concept studies / process development and scale-up / analytical development), scale of operation (preclinical, clinical and commercial) and location of manufacturing facilities. In addition, it provides details on the antibody contract manufacturers, HPAPI / cytotoxic payload contract manufacturers and biologics fill / finish service providers engaged in this domain.
Chapter 5 features a detailed competitiveness analysis of ADC contract manufacturers, based on manufacturing strength (on the basis of scale of operation and number of ADC manufacturing facilities), service strength (based on the number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities), supplier strength (in terms of employee count and years of experience in this field).
Chapter 6 Elaborate profiles of ADC contract manufacturers (shortlisted on the basis of competitiveness analysis). Each profile provides a brief overview of the company, its financial information, along with details on its ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
Chapter 7 provides a detailed analysis of the various expansion initiatives undertaken by service providers engaged in this domain, during the period 2012-2022, along with information on several relevant parameters, such as year of expansion, type of expansion (capacity expansion and new facility), type of service(s) offered (manufacturing services, analytical / development services and fill / finish services), location of expanded facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).
Chapter 8 presents an analysis of the recent partnerships inked between various players engaged in this domain. Additionally, it includes a brief description of the various types of partnership models (manufacturing agreements, product development agreements, research agreements, service alliance, acquisitions, product development and manufacturing agreements, licensing agreements, and others) that have been adopted by stakeholders engaged in this domain.
Chapter 9 presents a qualitative analysis highlighting the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.
Chapter 10 presents a detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stages.
Chapter 11 features an estimate of the overall ADC manufacturing / bioconjugation capacity (in kilograms) of contract manufacturers based on information provided by various industry stakeholders in the public domain. It also features the distribution of global capacity on the basis of company size (small, mid-sized and large), key geographical regions (North America, Europe and Asia-Pacific) and key players (in terms of highest bioconjugation capacity).
Chapter 12 provides an overview of the ADCs that are either approved or under development (clinical and preclinical), along with information on their current phase of development (marketed, clinical and preclinical / discovery stage), target indication(s), target antigen, antibody origin, antibody isotype, type of payload and type of linker.
Chapter 13 features a review of the evolution of ADC conjugation technologies, highlighting the various types of approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
Chapter 14 features an analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as number of trials registered, trial phase, trial status, target indication, type of sponsor / collaborator and number of patients enrolled.
Chapter 15 features an in-depth analysis of over 80 ADC based therapy developers that are likely to partner with contract service providers engaged in this domain, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of drugs in pipeline, their stage of development and type of target indication) and manufacturing capabilities.
Chapter 16 provides an informed estimate of the annual demand for ADC products (in kilograms), taking into account commercial, as well as clinical scale requirements, based on relevant parameters, such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
Chapter 17 provides a detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADCs in that particular geographical region.
Chapter 18 features a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
Chapter 19 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2035. The chapter provides likely distribution of the projected future opportunity based on phase of development (phase I, phase II and phase III), scale of operation (clinical and commercial), type of component manufacturing (antibody manufacturing, HPAPI / cytotoxic payload, linker and conjugation manufacturing, and fill / finish), target indications (solid tumors, hematological malignancies and others), type of payload (maytansinoid, auristatin, camptothecin, PBD and others), type of linker (SMCC, VC, malemide, peptide linker and others), type of antibody origin (humanized, chimeric, murine, human and others), type of antibody isotype (IgG1 and others) and geography (North America, Europe, Asia-Pacific, and Rest of the World).
Chapter 20 presents a discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.
Chapter 21 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), John Burt (ex-Chief Executive Officer, Abzena), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (ex-Director of CDMO, Pierre Fabre), David Cunningham (Director Corporate Development, Goodwin Biotechnology), Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (ex-Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (ex-Head of Bioconjugates Commercial Development, Lonza), Mark Wright (ex-Site Head, Piramal Pharma Solutions), Zhala Tawfiq (Associate Scientist, Ajinomoto Bio-Pharma Services), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO).
Chapter 22 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the ADC contract manufacturing market.
Chapter 23 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 24 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Components of Antibody Drug Conjugates (ADCs)
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Need for Outsourcing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
3.5. Key Considerations While Selecting a CMO Partner
3.6. Future Perspective
4. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturing Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis By Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Service(s) Offered
4.2.5. Analysis by Other ADC Service(s) Offered
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Location of Dedicated Manufacturing Facility
4.3. List of Antibody Contract Manufacturing Service Providers
4.4. List of HPAPI / Cytotoxic Payload Contract Manufacturing Service Providers
4.5. List of Biologics Fill / Finish Service Providers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. MabPlex
5.2.1. Company Overview
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Development and Future Outlook
5.3. AbbVie Contract Manufacturing
5.3.1. Company Overview
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Development and Future Outlook
5.4. Lonza
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. ADC Offerings
5.4.4. Manufacturing Facilities
5.4.5. Recent Development and Future Outlook
5.5. Catalent Pharma Solutions
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. ADC Offerings
5.5.4. Manufacturing Facilities
5.5.5. Recent Development and Future Outlook
5.6. Goodwin Biotechnology
5.6.1. Company Overview
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.4. Recent Development and Future Outlook
5.7. Piramal Pharma Solutions
5.7.1. Company Overview
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Development and Future Outlook
5.8. Millipore Sigma
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Development and Future Outlook
5.9. Abzena
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Development and Future Outlook
5.10. CARBOGEN AMCIS
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Development and Future Outlook
5.11. WuXi Biologics
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. ADC Offerings
5.11.4. Manufacturing Facilities
5.11.5. Recent Development and Future Outlook
5.12. Cerbios-Pharma
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Development and Future Outlook
5.13. Formosa Laboratories
5.13.1. Company Overview
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Development and Future Outlook
5.14. Creative Biolabs
5.14.1. Company Overview
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Recent Development and Future Outlook
5.15. Novasep
5.15.1. Company Overview
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Development and Future Outlook
5.16. Sterling Pharma Solutions
5.16.1. Company Overview
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Development and Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. ADC Contract Manufacturing Service Providers: Company Competitiveness Analysis
6.3.1. ADC Contract Manufacturing Service Providers based in North America
6.3.2. ADC Contract Manufacturing Service Providers based in Europe
6.3.3. ADC Contract Manufacturing Service Providers based in Asia-Pacific
7. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: RECENT EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturing Service Providers: Recent Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service(s) Offered
7.2.4. Analysis by Location of Expanded Facility
7.2.5. Analysis by Scale of Operation
7.2.6. Most Active Players: Analysis by Number of Expansions
8. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturing Service Providers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Service(s) Provided
8.3.4. Analysis by Scale of Operation
8.3.5. Most Active Players: Analysis by Number of Partnerships
8.3.6. Regional Analysis
8.3.6.1. Local and International Agreements
8.3.6.2. Intercontinental and Intracontinental Agreements
9. MAKE VERSUS BUY DECISION MAKING
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.2.1. Scenario 1
9.2.2. Scenario 2
9.2.3. Scenario 3
9.2.4. Scenario 4
9.3. Concluding Remarks
10. VALUE CHAIN ANALYSIS
10.1. Chapter Overview
10.2. ADC Development Value Chain
10.3. Cost Distribution Across the Value Chain
10.3.1. Cost Associated with Antibody Manufacturing
10.3.2. Cost Associated with Payload and Linker Manufacturing
10.3.3. Cost Associated with Conjugation
10.3.4. Cost Associated with Fill / Finish
11. ADC MANUFACTURING: CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. ADC Manufacturing: Global Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Headquarters
11.3.3. Analysis by Location of Manufacturing Facilities
11.3.3.1 Analysis by Country
11.3.3.2. Analysis by Continent
11.3.4. Analysis by Key Players
12. ADC THERAPEUTICS: MARKET OVERVIEW
12.1. Chapter Overview
12.2. List of ADC Therapeutics
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Target Disease Indication
12.2.3. Analysis by Target Antigen
12.2.4. Analysis by Antibody Isotype
12.2.5. Analysis by Type of Linker
12.2.6. Analysis by Payload / Warhead
12.2.7. Analysis by Type of Payload
12.3. Antibody Drug Conjugates: List of Therapy Developers
12.3.1. Analysis by Company Size and Location of Headquarters
12.3.2. List of Discontinued Drugs
13. NOVEL ADC CONJUGATION TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. First Generation ADC Technologies
13.3. Second Generation ADC Technologies
13.3.1. Cysteine and Selenocysteine Engineering
13.3.2. Unnatural Amino Acid Engineering
13.3.3. Amino-Terminal Serine Engineering
13.4. Third Generation ADC Technologies
13.4.1. Enzyme-Assisted Ligation Approaches
13.4.2. Glycan Remodeling Approaches
13.4.3. Ligation at Fab Nucleotide-Binding Site
13.4.4. Cysteine Rebridging
13.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
13.5. Other Emerging ADC Technologies
13.6. Evolutionary Analysis
14. CLINICAL TRIALS ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Therapeutics: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Trial Phase
14.3.3. Analysis by Trial Status
14.3.4. Analysis by Type of Payload
14.3.5. Analysis by Type of Linker
14.3.6. Analysis by Antibody Isotope
14.3.7. Most Active Players: Analysis by Number of Clinical Trials
14.3.8. Most Active Sponsors: Analysis by Number of Clinical Trials
14.3.9. Analysis by Number of Trials and Geography
14.3.10. Analysis by Number of Trials, Trial Status and Geography
14.3.11. Analysis by Enrolled Patient Population, Trial Status and Geography
14.4. ADC Therapeutics: Analysis by Antibody Isotope and Geography
14.4.1. IgG based Molecules
14.4.1.1. Analysis by Phase of Development and Geography
14.4.1.2. Analysis by Trial Status and Geography
14.4.1.3. Analysis by Enrolled Patient Population and Geography
14.4.2. IgG1 based Molecules
14.4.2.1. Analysis by Phase of Development and Geography
14.4.2.2. Analysis by Trial Status and Geography
14.4.2.3. Analysis by Enrolled Patient Population and Geography
14.4.3. IgG4 based Molecules
14.4.3.1. Analysis by Phase of Development and Geography
14.4.3.2. Analysis by Trial Status and Geography
14.4.3.3. Analysis by Enrolled Patient Population and Geography
14.4.4. Other Antibody Isotope based Molecules
14.4.4.1. Analysis by Phase of Development and Geography
14.4.4.2. Analysis by Trial Status and Geography
14.4.4.3. Analysis by Enrolled Patient Population and Geography
14.5. ADC Therapeutics: Analysis by Type of Payload and Geography
14.5.1. Auristatin based Molecules
14.5.1.1. Analysis by Phase of Development and Geography
14.5.1.2. Analysis by Trial Status and Geography
14.5.1.3. Analysis by Enrolled Patient Population and Geography
14.5.2. Calicheamicin (Ozogamicin) based Molecules
14.5.2.1. Analysis by Phase of Development and Geography
14.5.2.2. Analysis by Trial Status and Geography
14.5.2.3. Analysis by Enrolled Patient Population and Geography
14.5.3. Maytansine based Molecules
14.5.3.1. Analysis by Phase of Development and Geography
14.5.3.2. Analysis by Geography and Trial Status and Geography
14.5.3.3. Analysis by Enrolled Patient Population and Geography
14.5.4. Exatecan based Molecules
14.5.4.1. Analysis by Phase of Development and Geography
14.5.4.2. Analysis by Trial Status and Geography
14.5.4.3. Analysis by Enrolled Patient Population and Geography
14.5.5. Maytansinoid based Molecules
14.5.5.1. Analysis by Phase of Development and Geography
14.5.5.2. Analysis by Geography and Trial Status
14.5.5.3. Analysis by Geography and Enrolled Patient Population
14.5.2. Camptothecin based Molecules
14.5.6.1. Analysis by Phase of Development and Geography
14.5.6.2. Analysis by Trial Status and Geography
14.5.6.3. Analysis by Enrolled Patient Population and Geography
14.5.2. Other Payload based Molecules
14.5.7.1. Analysis by Phase of Development and Geography
14.5.7.2. Analysis by Trial Status and Geography
14.5.7.3. Analysis by Enrolled Patient Population and Geography
14.6. ADC Therapeutics: Analysis by Type of Linker and Geography
14.6.1. VC based Molecules
14.6.1.1. Analysis by Phase of Development and Geography
14.6.1.2. Analysis by Trial Status and Geography
14.6.1.3. Analysis by Enrolled Patient Population and Geography
14.6.2. Peptide Linker based Molecules
14.6.2.1. Analysis by Phase of Development and Geography
14.6.2.2. Analysis by Trial Status and Geography
14.6.2.3. Analysis by Enrolled Patient Population and Geography
14.6.3. Mc-Val-Cit-PABC based Molecules
14.6.3.1. Analysis by Phase of Development and Geography
14.6.3.2. Analysis by Trial Status and Geography
14.6.3.3. Analysis by Enrolled Patient Population and Geography
14.6.4. AcBut based Molecules
14.6.4.1. Analysis by Phase of Development and Geography
14.6.4.2. Analysis by Trial Status and Geography
14.6.4.3. Analysis by Enrolled Patient Population and Geography
14.6.5. SMCC based Molecules
14.6.5.1. Analysis by Phase of Development and Geography
14.6.5.2. Analysis by Trial Status and Geography
14.6.5.3. Analysis by Enrolled Patient Population and Geography
14.6.6. SPDB based Molecules
14.6.6.1. Analysis by Phase of Development and Geography
14.6.6.2. Analysis by Trial Status and Geography
14.6.6.3. Analysis by Enrolled Patient Population and Geography
14.6.7. Others Linker based Molecules
14.6.7.1. Analysis by Phase of Development and Geography
14.6.7.2. Analysis by Trial Status and Geography
14.6.7.3. Analysis by Enrolled Patient Population and Geography
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Key Potential Strategic Partners for ADC Therapeutics Developers
15.3.1. Likely Partner Opportunities in North America
15.3.2. Likely Partner Opportunities in Europe
15.3.3. Likely Partner Opportunities in Asia-Pacific
16. ADC THERAPEUTICS: DEMAND ANALYSIS
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. ADC Therapeutics: Overall Annual Demand
16.3.1. ADC Therapeutics: Annual Commercial Demand
16.3.1.1. Analysis by Type of Cancer
16.3.1.2. Analysis by Antibody Origin
16.3.1.3. Analysis by Antibody Isotype
16.3.1.4. Analysis by Type of Payload
16.3.1.5. Analysis by Type of Linker
16.3.1.6 Analysis by Key Geographical Regions
16.3.2. ADC Therapeutics: Annual Clinical Demand
16.3.2.1. Analysis by Phase of Development
16.3.2.2. Analysis by Type of Cancer
16.3.2.3. Analysis by Antibody Origin
16.3.2.4. Analysis by Antibody Isotype
16.3.2.5. Analysis by Type of Payload
16.3.2.6. Analysis by Type of Linker
16.3.2.7. Analysis by Key Geographical Regions
16.4. ADC Therapeutics: Demand and Supply Analysis
17. REGIONAL CAPABILITY ASSESSMENT ANALYSIS
17.1. Chapter Overview
17.2. Assumptions and Key Parameters
17.3. Regional Capability Assessment in North America
17.4. Regional Capability Assessment in Europe
17.5. Regional Capability Assessment in Asia-Pacific
17.6. Concluding Remarks
18. ATTRACTIVENESS COMPETETIVENESS MATRIX
18.1. Chapter Overview
18.2. AC Matrix: Overview
18.2.1. Strong Business Segment
18.2.2. Average Business Segment
18.2.3. Weak Business Segment
18.3. Analytical Methodology
18.4. AC Matrix: ADC Contract Manufacturing Scenario in North America
18.5. AC Matrix: ADC Contract Manufacturing Scenario in Europe
18.6. AC Matrix: ADC Contract Manufacturing Scenario in Asia Pacific
19. MARKET SIZING AND OPPORTUNITY ANALYSIS
19.1. Chapter Overview
19.2. Input Data and Key Assumptions
19.3. Forecast Methodology
19.4. Global ADC Therapeutics Market, 2022-2035
19.5. Global ADC Contract Manufacturing Market, 2022-2035
19.5.1. ADC Contract Manufacturing Market: Analysis by Type of Component Manufacturing, 2022-2035
19.5.2. ADC Contract Manufacturing Market: Analysis by Phase of Development, 2022-2035
19.6. ADC Contract Manufacturing Market for Commercial Products, 2022-2035
19.6.1. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Component Manufacturing, 2022-2035
19.6.1.1. ADC Contract Manufacturing Market for Commercial Products, Analysis by Antibody Origin, 2022-2035
19.6.1.2. ADC Contract Manufacturing Market for Commercial Products, Analysis by Antibody Isotype, 2022-2035
19.6.1.3. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Payload, 2022-2035
19.6.1.4. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Linker, 2022-2035
19.6.2. ADC Contract Manufacturing Market for Commercial Products, Analysis by Type of Cancer, 2022-2035
19.6.3. ADC Contract Manufacturing Market for Commercial Products, Analysis by Key Geographical Regions, 2022-2035
19.6.3.1. ADC Contract Manufacturing Market for Commercial Products in North America, 2022-2035
19.6.3.2. ADC Contract Manufacturing Market for Commercial Products in EU5, 2022-2035
19.6.3.3. ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2022-2035
19.7. ADC Contract Manufacturing Market for Clinical Products, 2022-2035
19.7.1. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Component Manufacturing, 2022-2035
19.7.1.1. ADC Contract Manufacturing Market for Clinical Products, Analysis by Antibody Origin, 2022-2035
19.7.1.2. ADC Contract Manufacturing Market for Clinical Products, Analysis by Antibody Isotype, 2022-2035
19.7.1.3. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Payload, 2022-2035
19.7.1.4. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Linker, 2022-2035
19.7.2. ADC Contract Manufacturing Market for Clinical Products, Analysis by Type of Cancer, 2022-2035
19.7.3. ADC Contract Manufacturing Market for Clinical Products, Analysis by Key Geographical Regions, 2022-2035
19.7.3.1. ADC Contract Manufacturing Market for Clinical Products in North America, 2022-2035
19.7.3.2. ADC Contract Manufacturing Market for Clinical Products in Europe, 2022-2035
19.7.3.3. ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2022-2035
19.7.3.4. ADC Contract Manufacturing Market for Clinical Products in MENA, 2022-2035
19.7.3.5. ADC Contract Manufacturing Market for Clinical Products in Latin America, 2022-2035
19.7.3.6. ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2022-2035
20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Strengths
20.3. Weaknesses
20.4. Opportunities
20.5. Threats
20.6. Comparison of SWOT Factors
21. CONCLUDING REMARKS
22. INTERVIEW TRANSCRIPTS
22.1. Chapter Overview
22.2. BSP Pharmaceuticals
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Aldo Braca (Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager)
22.3. Oxford BioTherapeutics
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Christian Rohlff (Chief Executive Officer & Founder)
22.4. Abzena
22.4.1. Company Snapshot
22.4.2. Interview Transcript: ex-John Burt (Chief Executive Officer)
22.5. Syndivia
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Sasha Koniev (Chief Executive Officer & Co-Founder)
22.6. Cerbios-Pharma
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Denis Angioletti (Chief Commercial Officer)
22.7. NBE-Therapeutics
22.7.1. Company Snapshot
22.7.2. Interview Transcript: Wouter Verhoeven (Chief Business Officer)
22.8. Eisai
22.8.1. Company Snapshot
22.8.2. Interview Transcript: Toshimitsu Uenaka (Executive Director and Takashi Owa, Chief Innovation Officer)
22.9. Synaffix
22.9.1. Company Snapshot
22.9.2. Interview Transcript: Anthony DeBoer (Director, Business Development)
22.10. Pierre Fabre
22.10.1. Company Snapshot
22.10.2. Interview Transcript: ex-Christian Bailly (Director of CDMO)
22.11. Goodwin Biotechnology
22.11.1. Company Snapshot
22.11.2. Interview Transcript: David Cunningham (Director Corporate Development)
22.12. Cerbios-Pharma
22.12.1. Company Snapshot
22.12.2. Interview Transcript: Vitor Sousa (Business Development Manager)
22.13. Catalent Pharma Solutions
22.13.1. Company Snapshot
22.13.2. Interview Transcript: Jennifer L. Mitcham (Director, Business Development and Stacy McDonald, ex-Group Product Manager)
22.14. Lonza
22.14.1. Company Snapshot
22.14.2. Interview Transcript: Laurent Ducry (ex-Head of Bioconjugates Commercial Development)
22.15. Piramal Pharma Solutions
22.15.1. Company Snapshot
22.15.2. Interview Transcript: Mark Wright (ex-Site Head)
22.16. Ajinomoto Bio-Pharma Services
22.16.1. Company Snapshot
22.16.2. Interview Transcript: Zhala Tawfiq (Associate General Manager)
22.17. Interview Transcript: Anonymous (Director, Business Development, Leading CMO)
22.18. Interview Transcript: Anonymous (Chief Executive Officer, Leading CMO)
23. APPENDIX I: TABULATED DATA
24. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Current Market Landscape of ADC Contract Manufacturing Service Providers
Figure 2.2 Executive Summary: Expansions
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Capacity Analysis
Figure 2.5 Executive Summary: Clinical Trial Analysis
Figure 2.6 Executive Summary: Demand Analysis
Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Key Components of an ADC
Figure 3.2 Manufacturing Steps of an ADC
Figure 3.3 Key Considerations While Selecting a CMO Partner
Figure 4.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 4.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
Figure 4.3 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 4.4 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Company Size
Figure 4.5 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Figure 4.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Service(s) Offered
Figure 4.7 ADC Contract Manufacturing Service Providers: Distribution by Other ADC Service(s) Offered
Figure 4.8 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 4.9 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) offered and scale of operation
Figure 4.10 ADC Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 5.1 Lonza: Annual Revenues, 2017-2021 (CHF Billion)
Figure 5.2 Catalent Pharma Solutions: Annual Revenues, 2017-2021 (USD Billion)
Figure 5.3 WuXi Biologics: Annual Revenues, 2017-2021 (RMB Billion)
Figure 6.1 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Asia-Pacific
Figure 7.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2022
Figure 7.2 Recent Expansions: Distribution by Type of Expansion
Figure 7.3 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 7.4 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
Figure 7.5 Recent Expansions: Distribution by Location of Expanded Facility
Figure 7.6 Recent Expansions: Distribution by Scale of Operation
Figure 7.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 7.8 Most Active Players: Distribution by Number of Expansions
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2012-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Service(s) Provided
Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Local and International Distribution
Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1 Make versus Buy: Decision Making Framework
Figure 9.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 10.1 Value Chain Analysis: ADC Development Overview
Figure 10.2 Value Chain Analysis: ADC Contract Manufacturing Overview
Figure 10.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
Figure 10.4 Value Chain Analysis: Distribution by Cost
Figure 10.5 Costs Associated with Antibody Manufacturing
Figure 10.6 Costs Associated with Payload and Linker Manufacturing
Figure 10.7 Costs Associated with Conjugation
Figure 10.8 Costs Associated with Fill / Finish
Figure 11.1 Overall Installed ADC Manufacturing Capacity: Distribution by Company Size
Figure 11.2 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Figure 11.3 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 11.4 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Continent-wise)
Figure 11.5 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Figure 12.1 ADC Therapeutics: Distribution by Phase of Development
Figure 12.2 ADC Therapeutics: Distribution by Target Disease Indication
Figure 12.3 ADC Therapeutics: Distribution by Target Antigen
Figure 12.4 ADC Therapeutics: Distribution by Antibody Isotype
Figure 12.5 ADC Therapeutics: Distribution by Type of Linker
Figure 12.6 ADC Therapeutics: Distribution by Type of Payload / Warhead
Figure 12.7 ADC Therapeutics: Distribution by Type of Payload
Figure 12.8 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
Figure 13.1 ADC Conjugation Platforms: Technological Evolution
Figure 13.2 ADC Conjugation Platforms: Technology Landscape
Figure 14.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.4 Clinical Trial Analysis: Distribution by Type of Payload
Figure 14.5 Clinical Trial Analysis: Distribution by Type of Linker
Figure 14.6 Clinical Trial Analysis: Distribution by Antibody Isotype
Figure 14.7 Most Active Players: Distribution by Number of Clinical Trials
Figure 14.8 Most Active Sponsors: Distribution by Number of Clinical Trials
Figure 14.9 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Figure 14.10 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Figure 14.11 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
Figure 14.12 Clinical Trial Analysis: Distribution by Antibody Isotype and Geography
Figure 14.13 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Phase of Development
Figure 14.14 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Trial Status
Figure 14.15 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Enrolled Patient Population
Figure 14.16 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Phase of Development
Figure 14.17 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status
Figure 14.18 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population
Figure 14.19 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Phase of Development
Figure 14.20 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status
Figure 14.21 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population
Figure 14.22 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Phase of Development
Figure 14.23 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Trial Status
Figure 14.24 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Enrolled Patient Population
Figure 14.25 Geographical Clinical Trial Analysis: Distribution by Type of Payload
Figure 14.26 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Phase of Development
Figure 14.27 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status
Figure 14.28 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Figure 14.29 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Phase of Development
Figure 14.30 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Trial Status
Figure 14.31 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Enrolled Patient Population
Figure 14.32 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Phase of Development
Figure 14.33 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Trial Status
Figure 14.34 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Enrolled Patient Population
Figure 14.35 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Phase of Development
Figure 14.36 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Trial Status
Figure 14.37 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Enrolled Patient Population
Figure 14.38 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Phase of Development
Figure 14.39 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status
Figure 14.40 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Figure 14.41 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Phase of Development
Figure 14.42 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status
Figure 14.43 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population
Figure 14.44 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Phase of Development
Figure 14.45 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status
Figure 14.46 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population
Figure 14.47 Geographical Clinical Trial Analysis: Distribution by Type of Linker
Figure 14.48 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Phase of Development
Figure 14.49 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status
Figure 14.50 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Figure 14.51 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Phase of Development
Figure 14.52 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status
Figure 14.53 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population
Figure 14.54 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Phase of Development
Figure 14.55 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Trial Status
Figure 14.56 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Enrolled Patient Population
Figure 14.57 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Phase of Development
Figure 14.58 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Trial Status
Figure 14.59 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Enrolled Patient Population
Figure 14.60 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Phase of Development
Figure 14.61 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status
Figure 14.62 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Figure 14.63 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Phase of Development
Figure 14.64 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status
Figure 14.65 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Figure 14.66 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Phase of Development
Figure 14.67 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status
Figure 14.68 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population
Figure 16.1 Global Demand for ADC Therapeutics, 2022-2035 (in kg)
Figure 16.2 Global Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
Figure 16.3 Global Annual Commercial Demand for ADC Therapeutics, 2022-2035 (in kg)
Figure 16.4 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
Figure 16.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Figure 16.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
Figure 16.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2022-2035 (in kg)
Figure 16.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2022-2035 (in kg)
Figure 16.9 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
Figure 16.10 Global Annual Clinical Demand for ADC Therapeutics, 2022-2035 (in kg)
Figure 16.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
Figure 16.12 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
Figure 16.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Figure 16.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
Figure 16.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2022-2035 (in kg)
Figure 16.16 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2022-2035 (in kg)
Figure 16.17 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
Figure 16.18 ADC Therapeutics: Demand and Supply Scenario, 2022-2035
Figure 17.1 Regional Capability Analysis: ADC Contract Manufacturing in North America
Figure 17.2 Regional Capability Analysis: ADC Contract Manufacturing in Europe
Figure 17.3 Regional Capability Analysis: ADC Contract Manufacturing in Asia-Pacific
Figure 17.4 Regional Capability Analysis: Comparison of Capabilities across Different Regions
Figure 18.1 AC Matrix: Pictorial Representation
Figure 18.2 AC Matrix: ADC Contract Manufacturing Scenario in North America
Figure 18.3 AC Matrix: ADC Contract Manufacturing Scenario in Europe
Figure 18.4 AC Matrix: ADC Contract Manufacturing Scenario in Asia Pacific
Figure 19.1 Global ADC Therapeutics Market, 2022-2035 (USD Billion)
Figure 19.2 ADC Therapeutics Market: Relative Cost of Manufacturing by Type of Component Manufacturing
Figure 19.3 Global ADC Contract Manufacturing Market, 2022-2035
Figure 19.4 ADC Contract Manufacturing Market: Distribution by Type of Component Manufacturing, 2022-2035
Figure 19.5 ADC Contract Manufacturing Market: Distribution by Phase of Development, 2022-2035
Figure 19.6 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Component Manufacturing, 2022-2035
Figure 19.7 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Origin, 2022-2035
Figure 19.8 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Isotype, 2022-2035
Figure 19.9 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Payload, 2022-2035
Figure 19.10 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Linker, 2022-2035
Figure 19.11 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Cancer, 2022-2035
Figure 19.12 ADC Contract Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035
Figure 19.13 ADC Contract Manufacturing Market for Commercial Products in North America, 2022-2035
Figure 19.14 ADC Contract Manufacturing Market for Commercial Products in EU5, 2022-2035
Figure 19.15 ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2022-2035
Figure 19.16 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Component Manufacturing, 2022-2035
Figure 19.17 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Origin, 2022-2035
Figure 19.18 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Isotype, 2022-2035
Figure 19.19 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Payload, 2022-2035
Figure 19.20 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Linker, 2022-2035
Figure 19.21 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Cancer, 2022-2035
Figure 19.22 ADC Contract Manufacturing Market for Clinical Products: Distribution by Key Geographical Regions, 2022-2035
Figure 19.23 ADC Contract Manufacturing Market for Clinical Products in North America, 2022-2035
Figure 19.24 ADC Contract Manufacturing Market for Clinical Products in Europe, 2022-2035
Figure 19.25 ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2022-2035
Figure 19.26 ADC Contract Manufacturing Market for Clinical Products in MENA, 2022-2035
Figure 19.27 ADC Contract Manufacturing Market for Clinical Products in Latin America, 2022-2035
Figure 19.28 ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2022-2035
Figure 20.1 SWOT Analysis: Harvey Ball Analysis
Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 21.1 Concluding Remarks: Current Market Landscape of ADC Contract Manufacturing Service Providers
Figure 21.2 Concluding Remarks: Recent Expansions
Figure 21.3 Concluding Remarks: Partnerships and Collaborations
Figure 21.4 Concluding Remarks: Capacity Analysis
Figure 21.5 Concluding Remarks: Clinical Trial Analysis
Figure 21.6 Concluding Remarks: Demand Analysis
Figure 21.7 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1 Common Cytotoxins Used for the Production of ADC Therapeutics
Table 3.2 Safebridge / OEL bands for HPAPI / Cytotoxic Payloads
Table 4.1 ADC Contract Manufacturing Service Providers: List of Companies
Table 4.2 ADC Contract Manufacturing Service Providers: Information on Type of Service(s) Offered
Table 4.3 ADC Contract Manufacturing Service Providers: Information on Other ADC Service(s) Offered
Table 4.4 ADC Contract Manufacturing Service Providers: Information on Scale of Operation
Table 4.5 ADC Contract Manufacturing Service Providers: Information on Location of Dedicated Manufacturing Facilities
Table 4.6 ADC Contract Manufacturing Service Providers: List of Antibody Manufacturing Service Providers,
Table 4.7 ADC Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Payloads Manufacturing Service Providers,
Table 4.8 ADC Manufacturing Service Providers: List of Biologics Fill / Finish Service Providers
Table 5.1 MabPlex: Company Overview
Table 5.2 MabPlex: ADC Related Offerings
Table 5.3 MabPlex: Information on Manufacturing Facilities
Table 5.4 MabPlex: Recent Developments and Future Outlook
Table 5.5 AbbVie Contract Manufacturing: Company Overview
Table 5.6 AbbVie Contract Manufacturing: ADC Related Offerings
Table 5.7 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 5.8 Lonza: Company Overview
Table 5.9 Lonza: ADC Related Offerings
Table 5.10 Lonza: Information on Manufacturing Facilities
Table 5.11 Lonza: Recent Developments and Future Outlook
Table 5.12 Catalent Pharma Solutions: Company Overview
Table 5.13 Catalent Pharma Solutions: ADC Related Offerings
Table 5.14 Catalent Pharma Solutions: Information on Manufacturing Facilities
Table 5.15 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 5.16 Goodwin Biotechnology: Company Overview
Table 5.17 Goodwin Biotechnology: ADC Related Offerings
Table 5.18 Goodwin Biotechnology: Information on Manufacturing Facilities
Table 5.19 Goodwin Biotechnology: Recent Developments and Future Outlook
Table 5.20 Piramal Pharma Solutions: Company Overview
Table 5.21 Piramal Pharma Solutions: ADC Related Offerings
Table 5.22 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 5.23 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 5.24 Millipore Sigma: Company Overview
Table 5.25 Millipore Sigma: ADC Related Offerings
Table 5.26 Millipore Sigma: Information on Manufacturing Facilities
Table 5.27 Millipore Sigma: Recent Developments and Future Outlook
Table 5.28 Abzena: ADC Related Offerings
Table 5.29 Abzena: Information on Manufacturing Facilities
Table 5.30 Abzena: Recent Developments and Future Outlook
Table 5.31 CARBOGEN AMCIS: Company Overview
Table 5.32 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 5.33 CARBOGEN AMCIS: Recent Developments and Future Outlook
Table 5.34 WuXi Biologics: Company Overview
Table 5.35 WuXi Biologics: ADC Related Offerings
Table 5.36 WuXi Biologics: Information on Manufacturing Facilities
Table 5.37 WuXi Biologics: Recent Developments and Future Outlook
Table 5.38 Cerbios-Pharma: Company Overview
Table 5.39 Cerbios-Pharma: ADC Related Offerings
Table 5.40 Cerbios-Pharma: Information on Manufacturing Facilities
Table 5.41 Cerbios-Pharma: Recent Developments and Future Outlook
Table 5.42 Formosa Laboratories: Company Overview
Table 5.43 Formosa Laboratories: ADC Related Offerings
Table 5.44 Formosa Laboratories: Information on Manufacturing Facilities
Table 5.45 Formosa Laboratories: Recent Developments and Future Outlook
Table 5.46 Creative Biolabs: Company Overview
Table 5.47 Creative Biolabs: ADC Related Offerings
Table 5.48 Creative Biolabs: Information on Manufacturing Facilities
Table 5.49 Creative Biolabs: Recent Developments and Future Outlook
Table 5.50 Novasep: Company Overview
Table 5.51 Novasep: ADC Related Offerings
Table 5.52 Novasep: Information on Manufacturing Facilities
Table 5.53 Novasep: Recent Developments and Future Outlook
Table 5.54 Sterling Pharma Solutions: Company Overview
Table 5.55 Sterling Pharma Solutions: ADC Related Offerings
Table 5.56 Sterling Pharma Solutions: Information on Manufacturing Facilities
Table 5.57 Sterling Pharma Solutions: Recent Developments and Future Outlook
Table 7.1 ADC Contract Manufacturing Service Providers: Recent Facility Expansions, 2012-2021
Table 8.1 ADC Contract Manufacturing Service Providers: Partnerships and Collaborations, 2012-2021
Table 10.1 ADC Component: Information on Cost by Type of Cytotoxin
Table 10.2 ADC Components: Information on Cost by Type of Linker
Table 11.1 Installed Global Capacity for ADC Manufacturing: Sample Data Set
Table 11.2 Installed Global Capacity for ADC Manufacturing: Sample Data Set (Average Capacity)
Table 11.3 Installed Global Capacity for ADC Manufacturing: Information on Total Capacity based on Company Size
Table 12.1 ADC Therapeutics: List of ADC Therapeutics
Table 12.2 ADC Therapeutics: List of Therapy Developers
Table 12.3 ADC Therapeutics: List of Discontinued Drugs
Table 13.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 13.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 13.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 13.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 13.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 13.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 13.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 13.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 15.1 Likely Partners for ADC Contract Manufacturers in North America
Table 15.2 Likely Partners for ADC Contract Manufacturers in Europe
Table 15.3 Likely Partners for ADC Contract Manufacturers in Asia-Pacific
Table 16.1 List of Late Stage ADCs
Table 16.2 ADC Therapeutics: Annual Demand for Outsourcing, 2022-2035 (in kg)
Table 16.3 ADC Therapeutics: Annual Supply for Outsourcing, 2022-2035 (in kgs)
Table 17.1 ADC Therapeutics: Development Status of Late Stage Candidates
Table 17.2 ADC Therapeutics: Outsourcing Activity for Late Stage Candidates
Table 20.1 ADC Therapeutics: Discontinued Drugs
Table 22.1 BSP Pharmaceuticals: Key Highlights
Table 22.2 Oxford BioTherapeutics: Key Highlights
Table 22.3 Abzena: Key Highlights
Table 22.4 Syndivia: Key Highlights
Table 22.5 Cerbios-Pharma: Key Highlights
Table 22.6 NBE-Therapeutics: Key Highlights
Table 22.7 Eisai: Key Highlights
Table 22.8 Synaffix: Key Highlights
Table 22.9 Pierre Fabre: Key Highlights
Table 22.10 Goodwin Biotechnology: Key Highlights
Table 22.11 Catalent Pharma Solutions: Key Highlights
Table 22.12 Lonza: Key Highlights
Table 22.13 Piramal Pharma Solutions: Key Highlights
Table 22.14 Ajinomoto Bio-Pharma Services: Key Highlights
Table 23.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 23.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
Table 23.3 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Table 23.4 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Company Size
Table 23.5 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
Table 23.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters and Service(s) Offered
Table 23.7 ADC Contract Manufacturing Service Providers: Distribution by Other ADC Service(s) Offered
Table 23.8 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
Table 23.9 ADC Contract Manufacturing Service Providers: Distribution by Type of Service(s) offered and scale of operation
Table 23.10 ADC Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Table 23.11 Lonza: Annual Revenues, 2017-2021 (CHF Billion)
Table 23.12 Catalent Pharma Solutions: Annual Revenues, 2017-2021 (USD Billion)
Table 23.13 WuXi Biologics: Annual Revenues, 2017-2021 (RMB Billion)
Table 23.14 Recent Expansions: Cumulative Year-wise Trend, 2012-2021
Table 23.15 Recent Expansions: Distribution by Type of Expansion
Table 23.16 Recent Expansions: Distribution by Type of Service(s) Offered
Table 23.17 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
Table 23.18 Recent Expansions: Distribution by Location of Expanded Facility
Table 23.19 Recent Expansions: Distribution by Scale of Operation
Table 23.20 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Table 23.21 Most Active Players: Distribution by Number of Expansions
Table 23.22 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2012-2021
Table 23.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 23.25 Partnerships and Collaborations: Distribution by Type of Service(s) Provided
Table 23.26 Partnerships and Collaborations: Distribution by Scale of Operation
Table 23.27 Most Active Players: Distribution by Number of Partnerships
Table 23.28 Partnerships and Collaborations: Local and International Distribution
Table 23.29 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.30 Overall Installed ADC Manufacturing Capacity: Distribution by Company Size
Table 23.31 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Table 23.32 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 23.33 Overall Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Continent-wise)
Table 23.34 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Table 23.35 ADC Therapeutics: Distribution by Phase of Development
Table 23.36 ADC Therapeutics: Distribution by Target Disease Indication
Table 23.37 ADC Therapeutics: Distribution by Target Antigen
Table 23.38 ADC Therapeutics: Distribution by Antibody Isotype
Table 23.39 ADC Therapeutics: Distribution by Type of Linker
Table 23.40 ADC Therapeutics: Distribution by Type of Payload / Warhead
Table 23.41 ADC Therapeutics: Distribution by Type of Payload
Table 23.42 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
Table 23.43 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 23.44 Clinical Trial Analysis: Distribution by Trial Phase
Table 23.45 Clinical Trial Analysis: Distribution by Trial Status
Table 23.46 Clinical Trial Analysis: Distribution by Type of Payload
Table 23.47 Clinical Trial Analysis: Distribution by Type of Linker
Table 23.48 Clinical Trial Analysis: Distribution by Antibody Isotype
Table 23.49 Most Active Players: Distribution by Number of Clinical Trials
Table 23.50 Most Active Sponsors: Distribution by Number of Clinical Trials
Table 23.51 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Table 23.52 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Table 23.53 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
Table 23.54 Geographical Clinical Trial Analysis: Distribution by Antibody Isotype and Geography
Table 23.55 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Phase of Development and Geography
Table 23.56 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Trial Status and Geography
Table 23.57 Geographical Clinical Trial Analysis (IgG based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.58 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Phase of Development and Geography
Table 23.59 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status and Geography
Table 23.60 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.61 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Phase of Development and Geography
Table 23.62 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status and Geography
Table 23.63 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.64 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Phase of Development and Geography
Table 23.65 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Trial Status and Geography
Table 23.66 Geographical Clinical Trial Analysis (Other Antibody Isotope based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.67 Geographical Clinical Trial Analysis: Distribution by Type of Payload and Geography
Table 23.68 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Phase of Development and Geography
Table 23.69 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status and Geography
Table 23.70 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.71 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Phase of Development and Geography
Table 23.72 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Trial Status and Geography
Table 23.73 Geographical Clinical Trial Analysis (Calicheamicin (Ozogamicin) based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.74 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Phase of Development and Geography
Table 23.75 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Trial Status and Geography
Table 23.76 Geographical Clinical Trial Analysis (Maytansine based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.77 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Phase of Development and Geography
Table 23.78 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Trial Status and Geography
Table 23.79 Geographical Clinical Trial Analysis (Exatecan based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.80 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Phase of Development and Geography
Table 23.81 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status and Geography
Table 23.82 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.83 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Phase of Development and Geography
Table 23.84 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status and Geography
Table 23.85 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.86 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Phase of Development and Geography
Table 23.87 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status and Geography
Table 23.88 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.89 Geographical Clinical Trial Analysis: Distribution by Type of Linker and Geography
Table 23.90 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Phase of Development and Geography
Table 23.91 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status and Geography
Table 23.92 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.93 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Phase of Development and Geography
Table 23.94 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status and Geography
Table 23.95 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.96 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Phase of Development and Geography
Table 23.97 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Trial Status and Geography
Table 23.98 Geographical Clinical Trial Analysis (Mc-Val-Cit-PABC based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.99 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Phase of Development and Geography
Table 23.100 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Trial Status and Geography
Table 23.101 Geographical Clinical Trial Analysis (AcBut based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.102 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Phase of Development and Geography
Table 23.103 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status and Geography
Table 23.104 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.105 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Phase of Development and Geography
Table 23.106 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status and Geography
Table 23.107 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.108 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Phase of Development and Geography
Table 23.109 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status and Geography
Table 23.110 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population and Geography
Table 23.111 Global Demand for ADC Therapeutics, 2022-2035 (in kg)
Table 23.112 Global Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
Table 23.113 Global Annual Commercial Demand for ADC Therapeutics, 2022-2035 (in kg)
Table 23.114 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
Table 23.115 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Table 23.116 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
Table 23.117 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload Type, 2022-2035 (in kg)
Table 23.118 Global Commercial Demand for ADC Therapeutics: Distribution by Type fo Linker, 2022-2035 (in kg)
Table 23.119 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
Table 23.120 Global Annual Clinical Demand for ADC Therapeutics, 2022-2035 (in kg)
Table 23.121 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2022-2035 (in kg)
Table 23.122 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2022-2035 (in kg)
Table 23.123 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Table 23.124 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2022-2035 (in kg)
Table 23.125 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2022-2035 (in kg)
Table 23.126 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2022-2035 (in kg)
Table 23.127 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2022-2035 (in kg)
Table 23.128 ADC Therapeutics: Demand and Supply Scenario, 2022-2035
Table 23.129 Global ADC Therapeutics Market, 2022-2035 (USD Billion)
Table 23.130 Global ADC Contract Manufacturing Market, 2022-2035
Table 23.131 ADC Contract Manufacturing Market: Distribution by Type of Component Manufacturing, 2022-2035
Table 23.132 ADC Contract Manufacturing Market: Distribution by Phase of Development, 2022-2035
Table 23.133 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Component Manufacturing, 2022-2035
Table 23.134 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Origin, 2022-2035
Table 23.135 ADC Contract Manufacturing Market for Commercial Products: Distribution by Antibody Isotype, 2022-2035
Table 23.136 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Payload, 2022-2035
Table 23.137 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Linker, 2022-2035
Table 23.138 ADC Contract Manufacturing Market for Commercial Products: Distribution by Type of Cancer, 2022-2035
Table 23.139 ADC Contract Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035
Table 23.140 ADC Contract Manufacturing Market for Commercial Products in North America, 2022-2035
Table 23.141 ADC Contract Manufacturing Market for Commercial Products in EU5, 2022-2035
Table 23.142 ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2022-2035
Table 23.143 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Component Manufacturing, 2022-2035
Table 23.144 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Origin, 2022-2035
Table 23.145 ADC Contract Manufacturing Market for Clinical Products: Distribution by Antibody Isotype, 2022-2035
Table 23.146 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Payload, 2022-2035
Table 23.147 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Linker, 2022-2035
Table 23.148 ADC Contract Manufacturing Market for Clinical Products: Distribution by Type of Cancer, 2022-2035
Table 23.149 ADC Contract Manufacturing Market for Clinical Products: Distribution by Key Geographical Regions, 2022-2035
Table 23.150 ADC Contract Manufacturing Market for Clinical Products in North America, 2022-2035
Table 23.151 ADC Contract Manufacturing Market for Clinical Products in Europe, 2022-2035
Table 23.152 ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2022-2035
Table 23.153 ADC Contract Manufacturing Market for Clinical Products in MENA, 2022-2035
Table 23.154 ADC Contract Manufacturing Market for Clinical Products in Latin America, 2022-2035
Table 23.155 ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2022-2035
The following companies and organizations have been mentioned in the report:
Discounts available for multiple report purchases
sales@rootsanalysis.com